Ingevity (NYSE:NGVT) CEO David Li Sells 5,000 Shares

Ingevity Corporation (NYSE:NGVT) CEO David Li sold 5,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $75.73, for a total transaction of $378,650.00. Following the transaction, the chief executive officer owned 125,636 shares in the company, valued at $9,514,414.28. This trade represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingevity Price Performance

Shares of NGVT stock opened at $74.01 on Wednesday. The firm has a market cap of $2.54 billion, a P/E ratio of 50.34 and a beta of 1.16. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. Ingevity Corporation has a 1-year low of $45.85 and a 1-year high of $79.29. The firm has a fifty day moving average of $73.84 and a two-hundred day moving average of $71.78.

Ingevity (NYSE:NGVT) last released its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The company had revenue of $314.10 million during the quarter, compared to the consensus estimate of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, research analysts anticipate that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of NGVT. Global Retirement Partners LLC bought a new stake in shares of Ingevity during the 4th quarter valued at about $27,000. Meeder Asset Management Inc. acquired a new stake in Ingevity during the fourth quarter worth about $33,000. Geneos Wealth Management Inc. lifted its holdings in Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after acquiring an additional 387 shares during the last quarter. Frazier Financial Advisors LLC bought a new position in Ingevity in the second quarter worth about $37,000. Finally, Headlands Technologies LLC acquired a new position in Ingevity in the second quarter valued at approximately $46,000. 91.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NGVT. Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Weiss Ratings upgraded Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Ingevity currently has an average rating of “Hold” and an average target price of $80.00.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.